SAN FRANCISCO--(BUSINESS WIRE)--Osteologix, Inc. (OTCBB: OLGX), a specialty pharmaceutical company, announced today data from a Phase I clinical study on its Dual Acting Bone Agent (DABA), NB S101. The data was presented at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting in Honolulu, Hawaii. The presentation entitled “Improved Strontium Bioavailability in a New Tablet Formulated Strontium Salt” demonstrated that the Company’s lead osteoporosis drug candidate, NB S101 (strontium malonate), had greater strontium bioavailability than a similar drug (strontium ranelate) approved for sale in Europe. The data presented to the international audience formed the basis for the Company’s Phase II clinical study evaluating the effect of NB S101 in modulating bone turnover and improving bone mineral density in women with low bone mass. Data from the Osteologix Phase II clinical trial will be reported the fourth quarter of 2007.
